Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis
Open Access
- 14 March 2025
- journal article
- review article
- Published by Springer Nature in Hepatology International
- Vol. 19 (3) , 607-618
Abstract
Background: Metabolic Dysfunction-Associated Fatty Liver disease (MAFLD) among lean individuals is increasingly recognized. We aimed to compare the prevalence, metabolic characteristics, and outcomes of lean vs overweight/obese-MAFLD patients. Methods: Databases of Embase, Medline, and Web of Science were searched from inception till October 2023. Only cohorts adhering to the lean-MAFLD criteria as defined by the international consensus statement were included. Results: In the pooled analysis of 10,013,382 individuals, the prevalence of lean-MAFLD in the general population was 1.94% (95% CI 1.10–3.39%, I 2 = 98.7%). Lean and overweight/obese-MAFLD patients had similar metabolic characteristics for blood pressure, LDL, TG, blood glucose, and HbA1c. There was an increased incidence rate and likelihood for liver-related mortality for lean-MAFLD vs overweight/obese-MAFLD [1.33 per 1000 patient-years (95% CI 1.28–1.39) vs 0.76 (95% CI 0.25–2.28), (OR 3.56 (95% CI 3.45–3.67), p < 0.01). There were similar incidence rates and odds ratios between lean vs overweight/obese-MAFLD for: (1) all-cause mortality [10.08 per 1000 patient-years (95% CI 9.93–10.23) vs 8.94 per 1000 patient-years (95% CI 4.08–19.57), (OR 1.92 (95% CI 0.01–220.57), p = 0.33)]; (2) cardiovascular-related mortality [2.53 per 1000 patient-years (95% CI 0.65–9.96) vs 2.07 per 1000 patient-years (95% CI 0.80–5.39), (OR 1.91 (95% CI 0.02–142.76), p = 0.58)]; and (3) cancer-related mortality [3.42 per 1000 patient-years (95% CI 3.33–3.51) vs 3.15 per 1000 patient-years (95% CI 1.21–8.19), (OR 1.99 (95% CI 0.29–13.52), p = 0.13). Conclusion: Lean-MAFLD patients have an equivalent metabolic burden compared to overweight/obese-MAFLD patients and thus a similar incidence rate of major extrahepatic complications. However, they have an increased risk of liver-related mortality. GraphicalKeywords
Funding Information
- University of Sydney
This publication has 30 references indexed in Scilit:
- Telomere length and mortality in lean MAFLD: the other face of metabolic adaptationHepatology International, 2024
- Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogrammingMetabolism, 2023
- Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b StudyClinical Gastroenterology and Hepatology, 2023
- Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysisJournal of Hepatology, 2022
- Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLDClinical Gastroenterology and Hepatology, 2021
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Normal weight obesity: Relationship with lipids, glycaemic status, liver enzymes and inflammationNutrition, Metabolism and Cardiovascular Diseases, 2010
- Meta‐analysis of skewed data: Combining results reported on log‐transformed or raw scalesStatistics in Medicine, 2008